FSFriday Saidi

Friday Saidi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Friday Saidi has a total of 275 co-authors. Here are the top co-authors by number of shared publications:

  • Benjamin H. Chi

    Affiliations Department of Obstetrics & Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America

    7 shared publications
  • Twambilile Phanga

    Affiliation UNC Project Malawi, Lilongwe, Malawi

    7 shared publications
  • Wilbroad Mutale

    Affiliation Department of Health Policy and Systems, University of Zambia, Lusaka, Zambia

    7 shared publications
  • Lameck Chinula

    University of North Carolina (UNC) Project Malawi, Lilongwe, Malawi

    6 shared publications
  • Irving Hoffman

    University of North Carolina (UNC) Project Malawi, Lilongwe, Malawi

    5 shared publications
  • K. Rivet Amico

    Affiliation Department of Health Behavior and Health Equity, University of Michigan, Ann Arbor, Michigan, United States of America

    5 shared publications

Latest Publications

  • Open Access

    Healthcare providers’ and policy-level stakeholders’ experiences on provision of post-abortion care and disclosure of abortion outside Malawi’s legal framework - a qualitative study

    by Funny Kamanga, Mallory Michalak, Wezi Dunda, Annie Thom, Lameck Chinula, Mercy Tsidya, Charity Nakanga, Gladwell Masiye, Agatha K. Bula, Mina C. Hosseinipour, et al.

    Background: Maternal deaths due to unsafe abortion remain a major public health challenge in sub-Saharan Africa. Malawi’s legal framework permits abortion only when the pregnancy poses a threat to the mother’s life, but a significant number of induced abortions are performed outside this legal framework and outside health facilities and/or by untrained healthcare providers. Although post-abortion care (PAC) is available to all women, regardless of whether the abortion was spontaneous or induced, legal, social and provider-related factors may influence women’s disclosure of unsafe abortions. To improve the provision of post-abortion care, it is essential to understand healthcare providers’ and policy stakeholders’ experiences with women’s disclosure of unsafe abortions. Methods: We conducted 16 in-depth interviews with healthcare providers and policy-level stakeholders serving patients needing post-abortion care. Semi-structured interview guides were used, and snowball sampling was used to identify participants. Interviews were audio-recorded and later transcribed. Data were coded in NVivo 12 using a deductive approach, and illustrative quotes were identified during analysis. Results: Healthcare providers and policy-level stakeholders described five interrelated factors that shaped women’s disclosure of unsafe abortion: (1) legal frameworks on abortion and fear of prosecution; (2) healthcare providers’ attitudes and perceptions, which were often less favorable toward women presenting with septic or induced abortion; (3) community-level stigma toward women known to have had an abortion; (4) religious beliefs particularly within Christian health facilities where abortion was seen as sinful; and (5) limited community awareness that PAC services were available. Overall, legal frameworks surrounding abortion in Malawi were perceived as a major barrier to disclosure and, subsequently, to women seeking post-abortion care. Conclusion: PAC provision in Malawi is shaped by an interplay of legal frameworks, health system capacity, and provider-patient dynamics. Addressing these issues will support timely disclosure of unsafe abortion. Timely disclosure, knowledge of and access to post- abortion care are key to minimising complications related to abortion. While abortion remains restricted by legal frameworks in Malawi, hospitals should be made more patient-centred in their delivery of post-abortion care.

  • Open Access

    Developing a surveillance system for HIV pre-exposure prophylaxis (PrEP) use in pregnancy in Malawi

    by Funny Kamanga, Madeleine A. Squibb, Watipa Nyangulu, William Wu, Jiehua Chen, Chatonda Ngwira, Anna Drabko, Wiktor Garbarek, Maciej Pomykala, Dominik Bilicki, et al.

    Background: Pregnant and breastfeeding women are at elevated risk of HIV acquisition. The World Health Organization (WHO) recommends use of oral TDF/FTC and long-acting injectables cabotegravir (CAB-LA) and lenacapavir (LEN) for HIV pre-exposure prophylaxis (PrEP) in pregnancy. However, safety data for emerging regimens remain limited due to the exclusion of pregnant women from early clinical trials and insufficient routine, program-embedded surveillance, especially in resource-constrained settings. In March 2024, as Malawi introduced CAB-LA, the PrEP Pregnancy Registry was established to generate real-world safety data on PrEP exposure during pregnancy. Methods: The PrEP Pregnancy Registry provides prospective safety surveillance of pregnant women on PrEP within routine service delivery across Malawi. Guided by the WHO collaborative framework for antiretroviral safety in pregnancy, the Registry was established through a phased process involving the Malawi Ministry of Health, research and implementing partners. Initially implemented at five CAB-LA early-access facilities, it was refined with provider feedback and expanded to 30 additional facilities. The registry utilizes ScanForm, an AI-powered tool that uses optical character recognition technology to digitize and analyze handwritten data. Birth outcomes are measured using WHO’s harmonized pharmacovigilance indicators for maternal and infant birth outcomes. Discussion: The Registry provides a scalable model for real-world pharmacovigilance of PrEP use in pregnancy. The use of ScanForm technology maximizes data quality and ensures integration with existing systems. Resulting evidence will fill critical gaps in PrEP safety data during pregnancy and inform national and global policies for integrating CAB-LA and emerging PrEP regimens into routine maternal health care settings. Trial Registration Numbers: The Pregnancy, Infant and Maternal Health Outcomes (PrIMO) sub-study within the Preventing Infant Infection with Implementation Science in Malawi (PRI 3 SM) was registered in ClinicalTrials.gov on 05th December 2023 with trial registration number NCT06158126, and the Path to Scale study was registered on 29th March 2024 with trial registration number NCT06319105.

  • Open Access

    Persistent human papillomavirus after thermal ablation in Malawian women with and without HIV: Implications for risk-based cervical cancer prevention in low- and middle-income countries

    by Jessica Gingles, Yating Zou, Lameck Chinula, Jennifer H. Tang, Ivy Kaliati, Tawonga Mkochi, Lizzie Msowoya, Charity Nakanga, Friday Saidi, Jennifer S. Smith, et al.

    Background: Persistent high-risk human papillomavirus (hrHPV) infection can lead to cervical precancer, with women living with HIV (WLWH) at increased risk due to impaired immune clearance. Thermal ablation (TA) is a low-cost treatment for precancerous lesions, but data on hrHPV persistence after TA among WLWH are limited. Objectives: To evaluate overall and channel-specific hrHPV persistence 12 months after TA among women in Lilongwe, Malawi. Design: Cross-sectional analysis of Malawian women who received TA during and after the PEER trial (prevention of cervical cancer through two HPV-based screen-and-treat implementation models in Malawi). Methods: We analyzed 495 hrHPV-positive women (113 WLWH, 382 without HIV) treated with TA. Self-collected cervicovaginal samples were obtained before treatment and at 12 months post-treatment and tested with the GeneXpert HPV assay, which detects hrHPV across five high-risk genotype channels (P1–P5). Channels P3–P5 were grouped as non-16/18/45 hrHPV types (HPV 31, 33, 35, 39, 51, 52, 56, 58, 59, 66, 68). Persistence was defined as the detection of the same channel at both time points. Differences in persistence rates were assessed using Fisher’s exact and Welch’s t -tests. Results: At 12 months post-TA, 35.6% of women were persistently hrHPV-positive. Persistence was higher among WLWH (46.0%) than women without HIV (32.0%, p = 0.01). By genotype, persistence was most common for non-16/18/45 types (37.7%), followed by HPV16 (28.9%) and HPV18/45 (18.0%). WLWH had higher persistence of non-16/18/45 types (51.8% versus 33.7% in HIV-negatives, p = 0.003), while persistence of HPV16 (35.0% versus 27.1%, p = 0.58) and HPV18/45 (26.3% versus 14.9%, p = 0.14) did not differ significantly. Conclusions: Over one-third of women had persistent hrHPV 12 months after TA, with higher rates among WLWH, primarily for non-16/18/45 genotypes. Findings highlight the need for enhanced follow-up and adjunct therapies to improve post-treatment clearance and advance cervical cancer prevention in low-resource settings.


  • Open Access

    Supporting Oral and Long-Acting HIV Preexposure Prophylaxis Decision-Making Among Pregnant Women (MyChoice Intervention): Protocol for 2 Pilot Randomized Controlled Trials

    by Friday Saidi, Symone Welch, Twambilile Phanga, Carlie Sulpizio, Lusubiro Paile, Doris Ngo'Ma, Mercy Tsidya, Mary Chindebvu, Grace Nkhoma, Lovemore Nkhalamba, et al.

    Background: HIV preexposure prophylaxis (PrEP) has potential for preventing HIV during the perinatal period, but few strategies promote person-centered shared decision-making (SDM) about PrEP use in these contexts. The MyChoice study aims to evaluate the feasibility, acceptability, and appropriateness of an SDM approach to support pregnant and breastfeeding women in Lilongwe, Malawi, integrating PrEP into antenatal care to encourage consistent use. Objective: Two pilot studies will assess the feasibility, acceptability, and appropriateness of an SDM intervention to support pregnant and breastfeeding women in making informed HIV prevention choices. The intervention will also explore the perspectives of participants, their male partners, and implementers. Each study compares the MyChoice intervention to standard-of-care PrEP counseling, with different HIV prevention method choices available. Methods: We will conduct 2 pilot randomized trials to evaluate the MyChoice intervention, designed to support PrEP decision-making among pregnant women in Lilongwe. Both studies will compare the MyChoice intervention to standard-of-care PrEP counseling. Study 1 will include 100 participants who will be offered oral PrEP and condoms for 3 months. Study 2 will include 50 participants who will be offered oral PrEP or injectable long-acting cabotegravir and condoms for 2 months. The primary end points for MyChoice study 1 are intervention acceptability, intervention appropriateness, and intervention feasibility, whereas for MyChoice study 2 they are intervention acceptability and intervention appropriateness. The secondary end point for MyChoice study 1 is decisional conflict, and for MyChoice study 2, it is the feasibility of study procedures. Exploratory end points include PrEP uptake assessment and dried blood spot measurement of PrEP adherence for MyChoice study 1 and PrEP uptake assessment for MyChoice study 2. Results: Data collection started on July 30, 2024, for study 1 and on February 10, 2025, for study 2. A total of 100 participants were enrolled in MyChoice study 1, and 50 participants were enrolled in MyChoice study 2. Study follow-up has been completed. Data analysis is expected to be completed by November 2025. Conclusions: The MyChoice pilot studies will provide critical evidence on a novel intervention for PrEP decision-making during pregnancy and breastfeeding. If feasible and acceptable, these results will form the basis for larger efficacy trials to promote PrEP uptake during pregnancy. Trial Registration: ClinicalTrials.gov NCT06394323; https://clinicaltrials.gov/study/NCT06394323 and ClinicalTrials.gov NCT06397690; https://www.clinicaltrials.gov/study/NCT06397690 International Registered Report Identifier (IRRID): DERR1-10.2196/76442

  • Open Access

    Alignment of PrEP adherence and HIV exposure risk among pregnant and postpartum women in Lilongwe, Malawi

    by Anna M. Leone, Friday Saidi, Lauren A. Graybill, Qinghua Li, Twambilile Phanga, Feng-Chang Lin, Twaambo E. Hamoonga, K. Rivet Amico, Wilbroad Mutale, Benjamin H. Chi

    Objective: When measured continuously, adherence to HIV pre-exposure prophylaxis (PrEP) is consistently low in studies of pregnant and postpartum women. We investigated how PrEP adherence aligned with HIV exposure risk. Methods: We conducted a trial of a PrEP adherence support intervention in Lilongwe, Malawi. Pregnant women who met eligibility criteria for PrEP had visits at three and six months following enrollment. At each visit, HIV exposure risk was categorized as low or moderate/high (i.e., higher) risk based on an algorithm. PrEP adherence was measured via tenofovir concentrations, with functional adherence defined at levels consistent with ≥4 doses/week. HIV exposure risk and PrEP adherence were classified as either aligned (i.e., higher HIV risk/PrEP adherence, low HIV risk/PrEP non-adherence) or not aligned (i.e., higher HIV risk/PrEP non-adherence, low HIV risk/PrEP adherence). Probability differences (PD) were used to estimate the effect of the PrEP adherence intervention on aligned PrEP adherence. Results: 164 women were included in the analysis. HIV exposure risk was higher for 81 participants (49%) at three months and 89 (54%) at six months. PrEP adherence was low at three months (34%) and at six months (29%). Aligned PrEP adherence was observed in 89 (54%) participants at three months and 83 (51%) at six months. 62% at higher HIV exposure risk were not aligned at month three, which increased to 68% at month six. The probability of aligned PrEP adherence was greater among those randomized to the intervention than those receiving standard of care at three months (PD:15.7%; 95%CI:0.8%, 30.6%). This was also evident in analyses that considered women with high HIV risk but low adherence. Conclusion: Alignment of PrEP adherence with HIV exposure risk was dynamic. PrEP adherence should be considered in the context of evolving HIV exposure risk during pregnancy and postpartum, with greater emphasis on periods of elevated HIV risk exposure.

  • Open Access

    Gestational diabetes and changes in dietary quality and food group consumption before and during pregnancy: a pilot cross-sectional study in Malawian women attending antenatal clinics

    by Getrude Mphwanthe, Friday Saidi, Maganizo B. Chagomerana, Oswin Kamangira, Priscilla Phiri, Charles Nyirongo, Triza Columbus, Lustia Mndoliro, Jonathan Misolo, Felistace Mtande, et al.

    This pilot cross-sectional study, conducted in two public hospitals in Malawi, assessed gestational diabetes mellitus (GDM) in pregnant women attending antenatal clinics and compared their dietary quality and food group consumption before and during pregnancy. The study targeted women aged 18 to 49 years within 24 to 28 weeks of gestation. GDM was diagnosed according to the International Association of Diabetes and Pregnancy Study Group criteria and assessed dietary quality before and during pregnancy using a 30-day qualitative food frequency questionnaire. We compared changes in dietary quality and specific food group mean scores using paired t-tests at p < 0.05. Of the 508 women enrolled, 22.7% were diagnosed with GDM. The overall diet quality significantly decreased during pregnancy compared to before; a similar trend was observed in women diagnosed with GDM compared to those without GDM (p < 0.0001). Among women with GDM, the mean score of the following food groups significantly (p < 0.05) decreased during pregnancy: cruciferous vegetables, deep orange vegetables and tubers, citrus fruits, deep orange fruits, other fruits, nuts and seeds, poultry, fish, low fat dairy, whole grains, and liquid oils and significantly (p < 0.05) increased in the following food groups; red meat, processed meat, sugar-sweetened beverages, sweets, sugary snacks and ice cream. In conclusion, GDM is prevalent in Malawian women enrolled in this study and is coupled with inadequate dietary quality, especially during pregnancy. Since dietary quality is pivotal to GDM management, more in-depth longitudinal dietary studies are needed to inform nutritional interventions to prevent and better manage GDM.

  • Open Access

    Long-Acting Injectable Antiretroviral Drugs for Pregnant and Breastfeeding Women: Current Advances, Challenges, and Future Directions

    by Friday Saidi, Mina C. Hosseinipour, Benjamin H. Chi

    This review explores the promise and challenges of integrating long-acting antiretroviral agents-cabotegravir, lenacapavir, and cabotegravir-rilpivirine-into HIV prevention and treatment programs for pregnant and breastfeeding populations. It aims to examine current evidence, implementation experiences, and barriers to equitable access. Emerging data support the efficacy and safety of long-acting agents during pregnancy and breastfeeding. Recent clinical trials have begun to include pregnant women by design, and national demonstration projects have successfully introduced injectable PrEP in maternal health settings. These developments signal growing recognition of the need for inclusive research and service delivery models. Long-acting antiretrovirals have the potential to transform maternal HIV prevention and treatment. However, challenges such as delayed inclusion in trials, policy constraints, limited product choice, high costs, and funding limitations persist. Addressing these gaps is critical to ensuring equitable access and informing future research and implementation strategies.


  • Open Access

    Understanding PrEP misconceptions and their impact on PrEP initiation and use among pregnant and lactating women in Malawi

    by Alinda M. Nyamaizi, Marley Catlett, Friday Saidi, Twambilile Phanga, Jennifer Tseka, Agatha Bula, Lisa D. Pearce, Suzanne Maman, Carol E. Golin, Wilbroad Mutale, et al.

    Mother-to-child transmission (MTCT) of HIV remains a challenge in Eastern and Southern Africa. Oral pre-exposure prophylaxis (PrEP) is a powerful tool to reduce MTCT, but women face barriers to effective use including those related to inaccurate comprehension of PrEP To understand women’s misconceptions about PrEP and their potential impact on PrEP use, we conducted interviews with 33 pregnant and lactating women in Malawi using PrEP, and ten PrEP counselors and clinicians. The results indicate that, although pregnant women generally understood PrEP’s features and functions, many held misconceptions that persisted over the course of their PrEP use and impacted their perceptions and use of the medication. Some women erroneously believed that PrEP could treat and prevent sexually transmitted infections other than HIV, which motivated some to keep taking PrEP while motivating others to stop using PrEP once their STI had resolved. Some were confused about PrEP’s function, with some believing it was the same as antiretroviral therapy for HIV treatment, and others believing that PrEP could be used for overall enhancement of health. Rarer misconceptions included fears that PrEP was connected to satanic practices, could cause cancer, or was solely for individuals engaged in sex work. These misconceptions stemmed from a mix of prior knowledge, societal influences, and miscommunications during counseling sessions. Ensuring accurate knowledge and addressing common misconceptions head-on is crucial to promote continued PrEP use among women. Both clinic- and community-based communication efforts with a particular focus on the difference between PrEP, STI treatments, and ART are needed.


  • Open Access

    Effect of initiation of antiretroviral drugs for HIV prevention or treatment on the vaginal microbiome of pregnant women in Malawi

    by Friday Saidi, Lauren A. Graybill, Jennifer H. Tang, Twambilile Phanga, Beteniko Milala, Gabriel Banda, Manley Kamija, Margaret Kasaro, Wilbroad Mutale, Joan Price, et al.

    Lack of Lactobacillus and/or dysbiosis is linked to spontaneous preterm birth (sPTB). The impact of antiretrovirals (ARVs) for HIV treatment or prevention on the vaginal microbiome during pregnancy remains unclear. We examined vaginal microbiome changes in pregnant women in Lilongwe, Malawi. Women living with HIV (WLHIV) initiated antiretroviral therapy (ART), while HIV-negative women began oral pre-exposure prophylaxis (PrEP). Of 255 participants (191 HIV-negative, 64 WLHIV) who provided baseline vaginal swabs, 181 provided follow-up swabs one month after ARV initiation. At enrollment, WLHIV had higher Shannon diversity and were more likely to have CST IV-B than CST I or III. After ARV initiation, α-diversity decreased in WLHIV but increased in HIV-negative women. Women initiating PrEP had a lower risk of sPTB compared to WLHIV initiating ART, but transitioning to CST IV during pregnancy increased the odds of sPTB. Larger studies are needed to explore ARV impact on pregnancy outcomes.


  • Assessing the Implementation Fidelity of a Patient-Centered, Combination Adherence Strategy to Support HIV Antiretroviral Therapy and Pre-Exposure Prophylaxis Adherence During Pregnancy and Breastfeeding in Malawi

    by Friday Saidi, Lauren A. Graybill, Twambilile Phanga, Katie R. Mollan, Getrude Msowoya, Mercy Tsidya, Mary Chindevu, Donnie Makonokaya, Kellie Freeborn, Nora E. Rosenberg, et al.

    The use of antiretroviral drugs has been proven effective in preventing and treating HIV; however, adherence remains a challenge. In two parallel pilot studies, we implemented a combination adherence intervention involving patient-centered counseling and adherence supporter training, tailored for HIV treatment (ART) or prevention (PrEP) during pregnancy and breastfeeding. The intervention included Integrated Next Step Counseling (iNSC), focused on well-being and medication adherence, with an option to involve a social support member. Independent auditors assessed implementation fidelity for 151 participants (51 women living with HIV and 100 PrEP-eligible women) by scoring iNSC sessions using a standard checklist. High fidelity was observed overall in both study populations, with variability between counselors observed. The results demonstrate the ability to assess implementation fidelity in a behavioral intervention aimed at supporting adherence to antiretroviral drugs among pregnant women and offers critical information on the complexities of implementation of iNSC in a real-world setting.